TP53 and urinary bladder carcinoma: demonstrated that immunogene therapy can be safely and effectively applied in the treatment of bladder cancer by applying an adenoviral vector‐mediated wildtype P53 gene for bladder perfusion therapy in patients with high‐stage bladder cancer.